Thermo Fisher Scientific Inc. (NYSE:TMO) Position Reduced by Castle Wealth Management LLC

Castle Wealth Management LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,283 shares of the medical research company’s stock after selling 166 shares during the quarter. Castle Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $1,213,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Wetzel Investment Advisors Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth about $107,000. Beaumont Financial Advisors LLC grew its position in Thermo Fisher Scientific by 1.5% during the fourth quarter. Beaumont Financial Advisors LLC now owns 2,182 shares of the medical research company’s stock valued at $1,158,000 after purchasing an additional 33 shares in the last quarter. Ninepoint Partners LP increased its stake in Thermo Fisher Scientific by 9.7% in the 4th quarter. Ninepoint Partners LP now owns 1,327 shares of the medical research company’s stock valued at $704,000 after buying an additional 117 shares during the period. Davidson Trust Co. boosted its stake in shares of Thermo Fisher Scientific by 10.8% during the 4th quarter. Davidson Trust Co. now owns 1,122 shares of the medical research company’s stock valued at $596,000 after buying an additional 109 shares during the period. Finally, HTLF Bank purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $782,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $3.27 during mid-day trading on Friday, hitting $544.79. The company’s stock had a trading volume of 1,738,319 shares, compared to its average volume of 1,549,865. The stock’s 50-day moving average is $571.27 and its two-hundred day moving average is $527.45. The firm has a market capitalization of $207.95 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the company earned $5.40 earnings per share. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TMO shares. Raymond James boosted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Royal Bank of Canada increased their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Finally, Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last 90 days. 0.32% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.